Navigation Links
New strategies with greater antitumorous efficacy
Date:10/2/2007

One of the biggest problems in the current treatment of cancer is that the agents that are efficacious in the destruction of tumorous cells are, at the same time, extremely toxic for the rest of the healthy cells and tissues of the patient. To address the problem the University of the Basque Country (UPV/EHU) is seeking more specific treatments and studying the differences between tumorous cells and healthy ones.

A research team from the Faculty of Medicine and Odontology is working on identifying pharmacological agents that increase the therapeutic benefit of combinations of chemo-, immune and radiotherapy agents in the treatment of cancer ailments.

The aim of the research team was to identify compounds that act on the metabolic pathways and processes that take place differently depending whether a diseased tissue of a patient or healthy tissue is involved; in this way selective action can be undertaken, increasing the sensitivity of treatments for diseased tissues without damaging healthy cells or tissues at the same time.

With this general goal the researchers tested various biomodulators on a number of different tumorous modules such as melanoma, sarcoma and cancer of the colon. On the one hand, they studied agents that modulated levels of glutathione (GSH) key element in the biological processes of cells, both healthy and tumorous. Tumorous cells with high GSH levels have a greater growth and metastatic capacity and a lower sensitivity to antitumorous agents. On the other hand, one of the features of tumorous cells is that they lose their normal level of differentiation and, instead of exercising a determined function, they start to proliferate and generate a greater quantity of tumorous cells. This is why the researchers have also used agents that induce differentiation, such as are retinoids.

More selective therapies

Both groups of modulators have been associated with classic agents used in antitumorous therapies and have seen the benefits arising therefrom. They have shown that the GSH level modulating agent - oxothiazolidine-carboxylate (OTZ) increases the antitumorous effect in antitumorous cells and, at the same time, protects healthy tissue. In this way the therapeutic benefit can be increased. Nevertheless, when another GSH-level modulating agent is combined with antitumorous agents, for example, buthionine-sulphoxamide (BSO), the researchers observed that the effect of the standard drug was increased but that an increase in damage to healthy tissue also took place.

Also, with the aim of returning the cells to a more differentiated state, closer to healthy cell behaviour, this research team is investigating the use of retinoids in combination with standard agents. The response of tumorous cells to retinoids depends on the degree of differentiation of these cells. In general, highly differentiated tumorous cells are more sensitive to retinoids than moderately differentiated ones are. These latter, in response to retinoids, may trigger defence mechanisms that augment GSH levels and, in this way, increase metastatic capacity.

This is an interesting point, given that to date this different capacity that can have different cell lines within the same tumorous type has not been described. What the UPV-EHU researchers have done is to link both lines of modulation -GSH modulation and that of the differentiation inductors. They have found a link between the two the induction of differentiation with retinoids also modulates the GSH levels of tumorous cells.

Researchers are analysing the model for the concentration and administering of the agents used, given that, in the biological modulation, both elements are found to be fundamental for the success of the treatment. The concentration is not a matter of the more the better, but the optimum response involves a specific concentration, because too little or too much may produce opposite or undesired effects.

Following in vitro and in vivo trials by researchers at the laboratories of the UPV/EHU, one of the goals of the research team is to transfer the information obtained to more easily managed systems for research and for clinical trials.


'/>"/>

Contact: Irati Kortabitarte
iratik@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Research on causes for falling helps develop preventive strategies
2. Strategies That Might Lower Blood Pressure Questioned
3. New Strategies For Effective Treatment Of Malaria
4. Experts State Strategies To Increase Good Cholesterol
5. Strategies to prevent the rising tide of the epidemic of chronic diseases
6. Vitamin A supplementation inadequate in India: Need for effective strategies
7. Strategies To Boost Living Donor Kidney Transplants
8. Japan planning Strategies to combat Bird flu
9. Need of the Hour: Viable Strategies against AIDS
10. Kellogg Warned Against Its Marketing Strategies
11. India to Spend Rs.10 bn on Polio Eradication Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... It's ... there are a number of illnesses that are unclear as to whether or not ... their heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into ...
(Date:4/28/2017)... ... ... affects much more than energy – it also has mental and physical benefits. According to ... time, which can increase the risk of having a car accident. , This week ... to help you sleep better and feel better:, , Turn off ...
(Date:4/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... election process has been in place since the RBMA was founded in 1968 with ... succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... America (UCAOA) and College of Urgent Care Medicine will host industry leaders for ... and speakers will help those in the industry adapt to the issues currently ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... Creator responds to and which He does not. Yisrayl says with so many titles ... the true name, but he says with a little Scripture, backed with a lot of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... EAST HANOVER, N.J. , April 19, 2017 ... study conducted by the National Heart, Lung, and ... Health (NIH) demonstrating that 58% of patients with ... at six months when treated with eltrombopag at ... treatment 1 . The study evaluated three sequential ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
Breaking Medicine Technology: